Iteos Therapeutics Inc
Change company Symbol lookup
Select an option...
ITOS Iteos Therapeutics Inc
MTLS Materialise NV
AFYA Afya Ltd
CSTR CapStar Financial Holdings Inc
ES Eversource Energy
AMKR Amkor Technology Inc
CMSC CMS Energy Corp
INTA Intapp Inc
OMCL Omnicell Inc
MPACU Model Performance Acquisition Corp
Go

Health Care : Biotechnology |
Company profile

iTeos Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovery and development of a differentiated immuno-oncology therapeutics for patients. The Company’s pipeline includes two clinical-stage programs EOS-448 and EOS-850. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system.

Postmarket

Last Trade
Delayed
$24.43
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$24.43
Day's Change
0.11 (0.45%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
24.65
Day's Low
24.08
Volume
(Light)
Volume:
163,992

10-day average volume:
244,323
163,992
  • Prev Close
    24.32
  • Today's Open
    24.21
  • Day's Range
    24.08-24.65
  • Avg Vol (10-day)
    244.3K
  • Last (time)
    4:00p ET 07/26/21
  • Last (size)
    4
  • 52-Wk Range
    17.43 - 47.61
    LowHigh
  • (03/03/21 - 06/04/21)
    40.16%
  • 78.8%
  • Market Cap
    857.6M
  • Shares Outstanding
    35.1M
  • -1.44
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 85.89
  • (% of float 06/30/21)
    2.41

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.